Advertisement

Topics

Gamida Cell Ltd. Company Profile

13:05 EST 15th December 2018 | BioPortfolio

Gamida Cell is developing expanded stem cell therapies for the treatment of such illnesses as blood cancers, cardiac disease and diabetes. The Company is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regeneration power of an ample body of therapeutic stem cells

Location

PO Box 34670
Jerusalem
91340
Israel

Contact

Phone: 972-54-536-5220
Email: marjie@gamida-cell.com


News Articles [1174 Associated News Articles listed on BioPortfolio]

Gamida Cell files for US IPO

Israeli cell therapeutics firm Gamida Cell Ltd. filed for its initial public offering on the Nasdaq Global Market.

IPO pulls in $50M for Gamida

An initial public offering brought in $50 million for Israeli cell therapy company Gamida Cell.  -More- 

Will Gamida Cell's NiCord Strike A Chord?

Shares of Gamida Cell Ltd. (GMDA) are up nearly 15% this month while the iShares Nasdaq Biotechnology ETF index (IBB) is down 1.55% for the same period.

5 Top Weekly NASDAQ Biotech Stocks: Gamida Cell Leads

Gamida Cell, AcelRx Pharmaceuticals, KalVista Pharmaceuticals, Evelo Biosciences and Magenta Therapeutics were last week's top gainers. The post 5 Top Weekly NASDAQ Biotech Stocks: Gamida Cell Leads a...

Gamida Cell netted $46.5mm in its US IPO

Israeli cell therapeutics firm Gamida Cell Ltd. netted $46.5mm in its initial public offering of 6.25mm ordinary shares at $8 each on the Nasdaq Global Market. The company planned to sell 3.57mm share...

Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will...

Israeli biotech Gamida files for IPO

Jerusalem-headquartered cellular and immune therapies company Gamida Cell has filed for a $69 million initial public offering on Nasdaq.

FDA grants orphan status to Gamida Cell's NiCord

The FDA designated orphan drug status to Gamida Cell's NiCord, being developed to treat patients who are eligible for a hemat -More- 

Drugs and Medications [19 Associated Drugs and Medications listed on BioPortfolio]

Sun care [Zenith Medicosm SL]

Drug Facts

Sun care [Zenith Medicosm SL]

Drug Facts

Alimta [Eli Lilly and Company]

These highlights do not include all the information needed to use ALIMTA safely and effectively. See full prescribing information for ALIMTA. ALIMTA (pemetrexed for injection) Lyophilized Powder, for ...

Hycamtin [GlaxoSmithKline LLC]

These highlights do not include all the information needed to use HYCAMTIN safely and effectively. See full prescribing information for HYCAMTIN. HYCAMTIN (topotecan) CapsulesInitial U.S. Approval: 19...

Patanol [Physicians Total Care, Inc.]

PubMed Articles [2523 Associated PubMed Articles listed on BioPortfolio]

Let curiosity lead you.

It is an incredible honor to receive the Woman in Cell Biology Mid-Career Award for Excellence in Research. My lab works on cell-cell fusion, an indispensable process in the conception, development, a...

Roles of ubiquitin in autophagy and cell death.

The balance between cell survival and cell death is often lost in human pathologies such as inflammation and cancer. Autophagy plays a critical role in cell survival: essential nutrients are generated...

B Cell Receptor Crosslinking Augments Germinal Center B Cell Selection when T Cell Help Is Limiting.

Antigen-dependent engagement of germinal center (GC) B cell receptors (BCRs) promotes antigen internalization and presentation for follicular helper T cells. However, whether BCR signaling is critica...

HIV-1-Infected CD4+ T Cells Facilitate Latent Infection of Resting CD4+ T Cells through Cell-Cell Contact.

HIV-1 is transmitted between T cells through the release of cell-free particles and through cell-cell contact. Cell-to-cell transmission is more efficient than cell-free virus transmission, mediates ...

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Clonal VDJ rearrangement of B/T cell receptors (B/TCRs) occurring during B/T lymphocyte development has been used as a marker to track the clonality of B/T cell populations.

Clinical Trials [6466 Associated Clinical Trials listed on BioPortfolio]

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation

The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients who have had a...

A Study for Patients With Non-Hodgkin's Lymphomas

In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and A...

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

The main purpose of this study is to explore the efficacy of CD19-targeted CAR-T cell therapy for minimal residual disease (MRD) in B-cell Malignancies after autologous stem cell transplan...

Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease

To determine the retinal and choroidal thickness in patients with sickle cell disease compared to age, race matched population without sickle cell disease to allow a better understanding o...

Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified

The purpose of this study is to monitor all patients exposed to an existing AUTO CAR T cell therapy, as well as the Sponsor's future autologous T cell products for up to 15 years following...

Companies [985 Associated Companies listed on BioPortfolio]

Gamida Cell Ltd.

Gamida Cell is developing expanded stem cell therapies for the treatment of such illnesses as blood cancers, cardiac disease and diabetes. The Company is dedicated to making a significant difference ...

Gamida Cell

Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The company’s pipel...

Elsevier and Cell Press

Cell Press, an imprint of Elsevier, is committed to improving scientific communication through the publication of exciting research and reviews. Each of our titles is viewed as a must-read by the ...

Cell Essentials, Inc.

Cell Essentials provides contract cell biology-based services facilitating the creation of reagents for use in diagnostics and drug discovery as well as basic research. Major services include the deve...

One Cell Systems, Inc.

One Cell Systems is developing and marketing a family of single cell assays that rely on microencapsulation and flow cytometry. Technology underlying these products has been developed internally and l...

More Information about "Gamida Cell Ltd." on BioPortfolio

We have published hundreds of Gamida Cell Ltd. news stories on BioPortfolio along with dozens of Gamida Cell Ltd. Clinical Trials and PubMed Articles about Gamida Cell Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Gamida Cell Ltd. Companies in our database. You can also find out about relevant Gamida Cell Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record